Looks to be as dry as a bone.
Related posts:
- Glaxo’s cancer pipeline
- Using cadaver bone during surgery: Sued for battery
- Pfizer: Going to the dogs
- Sermo and Pfizer
- More Sermo and Pfizer
- Pfizer fraud
- Pfizer gives up on cardiac drugs
KevinMD.com on Facebook
{ 3 comments }
They can always make an enantiomer of, say, detrol, and re-market it as a breakthrough new drug for overactive bladder. Worked for Astra-Zeneca and Nexium.
Here is the solution. Engineer an enantiomer of an existing drug like detrol LA, and re-patent it. Then market this “new” drug as a breakthough drug for over active bladder. Problem: solved. Alternatively they can combine 2 off-patent drugs, such as a detrol-hytrin combo drug, and sell this as a breakthrough agent. Perhaps they can call it Prostaspaz. With some marketing and FDA pay-outs, voila, a new blockbuster.
Dr Schoor, they’re already trying this crap with Caduet. Granted, Lipitor is still patent-protected, but it’s clear they’re thinking along the same lines. Torcetrapib was going to be their lifesaver. No more, I guess.
(Incidentally, Sanofi-Aventis has just done something similar with Xyzal.)
The very definition of “lame”.
I would be crapping my pants if I were the CEO of a big drug company right now. They’ve spent so much time and effort evergreening existing products that they’ve forgotten that basic research is the best way to make serious money. And that doing it effectively requires lots of time. Even companies with a product that’s actually better than the competition are undercapitalizing on their opportunities. It’s the height of folly.
I see a big crash in Big Pharma’s collective stock prices in the near future. It’s too late to effect a pipeline turnaround unless they buy a pre-existing company’s IP portfolio. And there just aren’t that many companies with much in the way of promising new drug therapies that can be bought out.
Comments on this entry are closed.